Blog
RSS FeedPosted by Michael Wonder on 01 Apr 2019
Assessing data sources for medicine price studies
29 March 2019 - There is no established methodology to assess the feasibility of medicine price data sources. ...
Posted by Michael Wonder on 29 Mar 2019
Cystic fibrosis scandal: drugs deal moves a step closer to saving children
27 March 2019 - Officials are set to meet again “soon” with US drugs giant Vertex to “break the current impasse” ...
Posted by Michael Wonder on 28 Mar 2019
Promising lung cancer treatment approved for Cancer Drugs Fund
28 March 2019 - A promising new lung cancer treatment will be available on the NHS through the Cancer Drugs Fund, ...
Posted by Michael Wonder on 28 Mar 2019
Take over pharma to create new medicines, says top adviser
27 March 2019 - Part of the drugs industry should be taken over to make new antibiotics, an influential economist ...
Posted by Michael Wonder on 27 Mar 2019
600 years’ supply of cystic fibrosis drug destroyed in price row
27 March 2019 - Nearly 8,000 packs of Orkambi, the breakthrough medicine for cystic fibrosis, have been destroyed by the ...
Posted by Michael Wonder on 27 Mar 2019
Charging for technology appraisals and highly specialised technologies
27 March 2019 - From 1 April 2019 NICE will charge for technology appraisal and highly specialised technologies assessments. ...
Posted by Michael Wonder on 27 Mar 2019
NICE recommendation for Steglatro in type 2 diabetes mellitus
27 March 2019 - NICE has recommended MSD’s Steglatro (ertugliflozin) for use within the NHS, for the treatment of adults ...
Posted by Michael Wonder on 26 Mar 2019
NICE at 20
26 March 2019 - Cost effectiveness body should stick to what it’s good at. ...
Posted by Michael Wonder on 25 Mar 2019
Pharma fears “lack of focus” on no-deal Brexit preparations
22 March 2019 - As Brexit is delayed, pharma suggests new measures to avoid no-deal drugs shortages. ...
Posted by Michael Wonder on 23 Mar 2019
NICE nod for Takeda’s Adcetris in advanced stage CTCL
22 March 2019 - Takeda has announced the NICE recommendation of its advanced cutaneous T-cell lymphoma drug Adcetris (brentuximab vedotin). ...
Posted by Michael Wonder on 21 Mar 2019
NICE terminates yet another assessment of a cancer medicine
20 March 2019 - This time it is pembrolizumab (Keytruda). ...
Posted by Michael Wonder on 21 Mar 2019
Is Orkambi deal close? Vertex meets again today with NHS England
21 March 2019 - Campaigners hopes rise after three year wait. ...
Posted by Michael Wonder on 20 Mar 2019
York man Paul Thomas-Peter says he could die because NHS won't fund drug
19 March 2019 - A York cancer patient says he could die because the NHS refuses to fund immunotherapy treatment ...
Posted by Michael Wonder on 20 Mar 2019
Unprecedented drug shortage linked to Brexit, NHS bosses say
20 March 2019 - Hospitals across England are experiencing medicine shortages due to "stockpiling and price pressure as the Brexit ...
Posted by Michael Wonder on 20 Mar 2019
The shadow of Brexit on speed of access
20 March 2019 - No-one can miss the ongoing saga that is the UK’s exit from the European Union. ...